Patents by Inventor Sarah YOON

Sarah YOON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for prediction of susceptibility to sorafenib treatment by using SULF2 gene, and composition for treatment of cancer comprising SULF2 inhibitor
    Patent number: 11510911
    Abstract: The present invention relates to a method for predicting susceptibility to sorafenib treatment by using an SULF2 gene, and a composition for treatment of sorafenib-resistant cancer using the SULF2 expression inhibition. The method for predicting susceptibility to sorafenib treatment by using the SULF2 gene according to the present invention can enable achievement of an optimal therapeutic effect by administering a drug suitable for cancer patients, and the composition for treatment of sorafenib-resistant cancer using the SULF2 inhibition has a very excellent anticancer treatment effect.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: November 29, 2022
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Hyun Goo Woo, Sarah Yoon, Eun-Ju Lee
  • BISPECIFIC ANTIGEN-BINDING MOLECULE
    Publication number: 20200181264
    Abstract: Provided herein relates to antigen-binding molecules, in particular bispecific antigen-binding molecules that bind to a cancer cell antigen and an immune cell surface molecule.
    Type: Application
    Filed: August 10, 2018
    Publication date: June 11, 2020
    Inventors: John J. Rossi, Sarah Yoon, Piotr Marek Swiderski, Nagy Habib, John Ernest Shively
  • METHOD FOR PREDICTION OF SUSCEPTIBILITY TO SORAFENIB TREATMENT BY USING SULF2 GENE, AND COMPOSITION FOR TREATMENT OF CANCER COMPRISING SULF2 INHIBITOR
    Publication number: 20200085802
    Abstract: The present invention relates to a method for predicting susceptibility to sorafenib treatment by using an SULF2 gene, and a composition for treatment of sorafenib-resistant cancer using the SULF2 expression inhibition. The method for predicting susceptibility to sorafenib treatment by using the SULF2 gene according to the present invention can enable achievement of an optimal therapeutic effect by administering a drug suitable for cancer patients, and the composition for treatment of sorafenib-resistant cancer using the SULF2 inhibition has a very excellent anticancer treatment effect.
    Type: Application
    Filed: March 20, 2018
    Publication date: March 19, 2020
    Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Hyun Goo WOO, Sarah YOON, Eun-Ju LEE